First published on
While attention focused on iRhythm Technologies after Medicare rates for long-term cardiac monitoring were slashed in January, the fallout is now extending to other players and the future of the much-hyped market is being questioned.
Novitas Solutions, which sets regional Medicare rates as a Medicare Administrative Contractor, is working with iRhythm and rivals about possibly changing the published rates. However, there is no timetable for when or if the rates will change, leaving Wall Street and industry in a holding pattern.
Baird Equity Research analyst Mike Polark said that the reimbursement uncertainty makes any long-term growth expectation for iRhythm and the overall cardiac wearables market difficult.
Share it
While attention focused on iRhythm Technologies after Medicare rates for long-term cardiac monitoring were slashed in January, the fallout is now extending to other players and the future of the much-hyped market is being questioned.
Novitas Solutions, which sets regional Medicare rates as a Medicare Administrative Contractor, is working with iRhythm and rivals
about possibly changing the published rates. However, there is no timetable for when or if the rates will change, leaving Wall Street and industry in a holding pattern.
Baird Equity Research analyst Mike Polark said that the reimbursement uncertainty makes any long-term growth expectation for iRhythm and the overall cardiac wearables market difficult.
email article
Not every cancer drug approved by the FDA receives approval and coverage in England and Canada, two studies in
JAMA Internal Medicine showed.
In England, a retrospective cohort study looked at 68 drugs given accelerated approval by the FDA from December 1992 to May 2017 that also received market approval in the European Union. The researchers, Elias Mossialos, MD, PhD, of the London School of Economics and Political Science, and colleagues, found that only 45 drug indications (66.2%) were recommended for public coverage through the National Health Services (NHS), and that 39 of the 45 (86.7%) were recommended only after price negotiation or collection of further data to verify the clinical benefit.
The Smoke in Smoking - Perspective propakistani.pk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from propakistani.pk Daily Mail and Mail on Sunday newspapers.
Feb 11, 2021 11:08am
Novo Nordisk estimates that only 10% of 650 million people with obesity currently seek medical treatment, leaving the market wide open for its drug semaglutide. (Creative Commons CC0)
Novo Nordisk has taken one step forward in its ambition to move its Type 2 diabetes drug semaglutide into the giant and largely untapped obesity market. And despite the failure of past obesity drugs not to mention lackluster sales of Novo’s own weight loss product Saxenda the company’s executives now have even more reason to be optimistic.
Data from a phase 3 trial released Wednesday night showed that one-third of patients taking semaglutide, a GLP-1 agonist, lost more than 20% of their body weight during the 68-week trial. The average participant lost more than 33 pounds, and many saw improvements in risk factors for diabetes and heart disease, according to University College London, one of the principle trial sites. The study was published in the New England Journal of Medi